Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Alterome Therapeutics, Inc.
Alterome Therapeutics Appoints Leo Faoro, MD, MBA, as Chief Medical Officer
February 02, 2026
From
Alterome Therapeutics, Inc.
Via
Business Wire
Alterome Therapeutics Announces New Chief Executive Officer and Chair of the Board of Directors
April 10, 2025
From
Alterome Therapeutics, Inc.
Via
Business Wire
Alterome Doses First Patient in Phase 1 Study of ALTA3263, a Novel Pan-KRAS Dual ON/OFF Inhibitor, in Advanced Solid Tumors
March 10, 2025
From
Alterome Therapeutics, Inc.
Via
Business Wire
Alterome Therapeutics to Participate in Upcoming Investor Conferences
February 25, 2025
From
Alterome Therapeutics, Inc.
Via
Business Wire
Alterome Therapeutics Announces First Patient Dosed in Phase 1 Study of ALTA2618 in AKT1 E17K-mutant solid tumors (AKTive-001)
October 30, 2024
From
Alterome Therapeutics, Inc.
Via
Business Wire
Alterome Therapeutics to Present Preclinical Data for its KRAS Selective Inhibitor ALTA3263 at the 2024 ENA Symposium
October 25, 2024
From
Alterome Therapeutics, Inc.
Via
Business Wire
Eric Murphy, Ph.D., Co-Founder and CEO of Alterome, Named to Goldman Sachs Top 100 Most Exceptional Entrepreneurs at 2024 Builders and Innovators Summit
October 17, 2024
From
Alterome Therapeutics, Inc.
Via
Business Wire
Alterome Therapeutics Presents Pre-Clinical Data Supporting the Development of Lead Program, an AKT1 E17K Inhibitor
April 08, 2024
From
Alterome Therapeutics, Inc.
Via
Business Wire
Alterome Therapeutics Raises $132 Million in Series B Financing Led by Goldman Sachs Alternatives
April 03, 2024
From
Alterome Therapeutics, Inc.
Via
Business Wire
Alterome Therapeutics Welcomes Andrew S. Chi, M.D., Ph.D., as Chief Medical Officer
August 23, 2023
From
Alterome Therapeutics, Inc.
Via
Business Wire
Alterome Therapeutics Establishes Scientific Advisory Board Comprised of Renowned Oncology Experts
January 05, 2023
From
Alterome Therapeutics, Inc.
Via
Business Wire
Alterome Therapeutics Extends Series A to Nearly $100 Million to Advance Alteration-Specific Cancer Therapies
November 02, 2022
From
Alterome Therapeutics, Inc.
Via
Business Wire
Alterome Therapeutics Launches With $64M Series A Financing
January 19, 2022
From
Alterome Therapeutics, Inc.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.